A randomized phase 2 trail of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in unresectable or borderline resectable pancreatic adenocarcinoma: The ghost regimen strikes back

Category Primary study
JournalPancreatology
Year 2017
This article has no abstract
Epistemonikos ID: b9bbbc250043cc88854f1417c52711ae7e861756
First added on: Feb 08, 2025